Open AccessLong-Term Molecular Remission Achieved by Antibody Anti-CD22 and Ponatinib in a Patient Affected by Ph’+ Acute Lymphoblastic Leukemia Relapsed after Second Allogeneic Hematopoietic Stem Cell Transplantation: A Case Report
Author(s) -
Maria Cristina Pirosa,
Salvatore Leotta,
Alessandra Cupri,
Stefania Stella,
Enrica Antonia Martino,
Luca Scalise,
Giuseppe Sapienza,
Valeria Calafiore,
Elisa Mauro,
Andrea Spadaro,
Paolo Vigneri,
Francesco Di Raimondo,
Giuseppe Milone
Publication year - 2018
Publication title -
chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.539
H-Index - 54
eISSN - 1421-9794
pISSN - 0009-3157
DOI - 10.1159/000492941
Subject(s) - ponatinib , medicine , hematopoietic stem cell transplantation , oncology , transplantation , blinatumomab , stem cell , leukemia , tyrosine kinase , immunology , lymphoblastic leukemia , dasatinib , biology , receptor , genetics
Ph’+ acute lymphoblastic leukemia (Ph’+-ALL) is an oncohematologic disorder for which allogeneic bone marrow transplantation still offers the only chance of cure. However, relapse is the main reason for treatment failure, also after hematopoietic stem cell transplantation (HSCT). New drugs, such as third generation tyrosine kinase inhibitors (TKIs) and monoclonal antibodies, have expanded the therapeutic landscape, especially in patients who relapsed before HSCT. Very few reports, up to now, have described the use of both classes of these new agents in combination with donor lymphocyte infusions (DLI) in the setting of patients who relapsed after HSCT. We report on a young patient affected by Ph’+-ALL, who relapsed after the second HSCT and who reached molecular remission and long-term disease control by treatment with the anti-CD22 monoclonal antibody inotuzumab ozogamicin, DLI, and the 3rd generation TKI ponatinib.